Telix Pharmaceuticals Limited (TLX)
NASDAQ: TLX · Real-Time Price · USD
10.54
+0.74 (7.55%)
At close: Apr 10, 2026, 4:00 PM EDT
10.21
-0.33 (-3.13%)
After-hours: Apr 10, 2026, 7:36 PM EDT
Telix Pharmaceuticals Employees
As of December 31, 2025, Telix Pharmaceuticals had 1,184 total employees, including 1,120 full-time and 64 part-time employees. The number of employees increased by 950 or 405.98% compared to the previous year.
Employees
1,184
Change
950
Growth
405.98%
Revenue / Employee
$678,880
Profits / Employee
-$6,018
Market Cap
3.52B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 1,184 | - | - | 1,120 | 64 |
| Mar 31, 2024 | 431 | 197 | 84.19% | 415 | 16 |
| Dec 31, 2022 | 234 | 76 | 48.10% | 234 | 0 |
| Dec 31, 2021 | 158 | - | - | 158 | 0 |
| Dec 31, 2017 | 9 | - | - | 9 | 0 |
Related Stocks
| Company Name | Employees |
|---|---|
| Legend Biotech | 2,965 |
| ACADIA Pharmaceuticals | 798 |
| Denali Therapeutics | 503 |
| Tarsus Pharmaceuticals | 370 |
| Arcutis Biotherapeutics | 354 |
| Dyne Therapeutics | 258 |
| Structure Therapeutics | 220 |
| Catalyst Pharmaceuticals | 182 |
TLX News
- 16 hours ago - Telix Pharmaceuticals Shares Jump 7% on FDA Nod for Brain Cancer Imaging Agent Amid Strong Revenue Momentum - International Business Times (Australia)
- 17 hours ago - Telix Seeks Reset With FDA Filing While Sales Growth Holds Steady - Benzinga
- 17 hours ago - Telix Pharmaceuticals (TLX) Sees 7% Gain Following FDA Acceptance of Imaging Agent - GuruFocus
- 23 hours ago - ASX 200 Top Gainers: Telix Pharma Jumps 3.23% on FDA Nod as Healthcare Leads Mixed Session Amid Oil Rebound - International Business Times (Australia)
- 1 day ago - FDA Accepts NDA for TLX101-Px (Pixclara®) - GlobeNewsWire
- 2 days ago - Telix Strengthens Board with Additional Director Appointments - GlobeNewsWire
- 3 days ago - Why Is Telix Pharma Stock Soaring Tuesday? - Benzinga
- 3 days ago - Telix Pharmaceuticals Stock Rises 5% Over Strong Revenue Growth In Q1 - Nasdaq